WO2012019533A1 - Electronic cigarette's atomization composition with calcium pectate gel and preparation process and use thereof - Google Patents
Electronic cigarette's atomization composition with calcium pectate gel and preparation process and use thereof Download PDFInfo
- Publication number
- WO2012019533A1 WO2012019533A1 PCT/CN2011/078133 CN2011078133W WO2012019533A1 WO 2012019533 A1 WO2012019533 A1 WO 2012019533A1 CN 2011078133 W CN2011078133 W CN 2011078133W WO 2012019533 A1 WO2012019533 A1 WO 2012019533A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- parts
- water
- acid
- propylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Definitions
- the invention relates to an electronic aerosolization composition and a preparation method thereof, and also relates to a calcium pectate gel and a preparation method and application thereof.
- the structure of an electronic cigarette generally includes an atomizer.
- Conventional electronic cigarettes often bond the atomizer to the mouthpiece to make a disposable atomizer.
- the structure of the prior art atomizer is a temperature-increasing component, which is heated by a battery to cause the smoke oil adjacent to it to volatilize, forming a smoke, thereby achieving the effect of "swallowing clouds and spitting" when sucking.
- the technical problem to be solved by the present invention is to provide an electronic aerosolized composition capable of maintaining a solid paste and a preparation method thereof.
- the present invention also provides a calcium pectate gel which makes the atomization effect more stable, and a preparation method and application thereof.
- An electronic aerosol composition comprising the following components in a weight ratio: excipient 2 ⁇ 3. 0 parts, curing agent 0. 3 ⁇ 0. 8 parts, propylene glycol or glycerol 10 ⁇ 70 parts, water 5 ⁇ 25 copies.
- the propylene glycol or glycerol is a commercially available product.
- water is a solvent, that is, the solvent of the present invention is three kinds, one is a mixture of propylene glycol and water, one is a mixture of glycerin and water, and the other is propylene glycol, glycerin, a mixture of water.
- the metering of the present invention is measured by mixing together propylene glycol and glycerol.
- a solvent solution of a mixture of propylene glycol, glycerol, and water is not employed.
- the excipient comprising the following components: xanthan gum and casein phosphopeptides, the weight ratio of the excipient is 0. 25 ⁇ 0. 67.
- xanthan gum and casein phosphopeptides are commercially available products having thickening and binding effects.
- propylene glycol citrate and sodium alginate are commercially available products.
- the electronic aerosolizing composition can be formed into a solid, creamy substance, similar to a toothpaste. 5 ⁇ The composition of the composition of the weight ratio of the following components: the calcium pectate gel 0. 2 ⁇ 1. 0 parts. This fraction is calculated based on the overall composition of the electronic aerosolized composition.
- the calcium pectate gel has a raw material comprising 5 to 15% of fruit acid, 20 to 40% of gelatin, 40 to 60% of water, and 15 to 20% of glycerin.
- the fruit acid is one of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid or a combination thereof.
- the role of the calcium pectate gel in the electronic aerosolization composition is to enhance its stability upon atomization. It is to be noted that the parts in the specification of the present invention are calculated based on the overall composition of the electronic aerosolized composition, unless otherwise specified.
- composition further comprising the following components by weight: 30 ⁇ 35 parts of the medicament, or / and the tobacco extract 3 ⁇ 3. 5 parts, or / and the flavor of the tobacco 3 ⁇ 3.
- the tobacco extract is a commercially available tobacco extract, more preferably a tobacco extract, such as a cloud smoke extract.
- the tobacco flavor preferably, is a commercially available flavor.
- the medicament comprises the following components: Gynostemma extract, German chamomile extract, casein phosphopeptide, dandelion extract, astragalus extract, honeysuckle extract, Chuanbei extract, chrysanthemum extract, lily extract, wood
- Gynostemma extract German chamomile extract, casein phosphopeptide, dandelion extract, astragalus extract, honeysuckle extract, Chuanbei extract, chrysanthemum extract, lily extract, wood
- the above agents are commercially available agents.
- the composition of the drug in the weight percentage of the drug is: Gynostemma pentaphyllum extract 25 ⁇ 30. 0%, German chamomile extract 5 ⁇ 20. 0%, casein phosphopeptide 5 ⁇ 20. 0%, Dandelion extract 5 ⁇ 15. 0%, Astragalus extract 3 ⁇ : 15. 0%, honeysuckle extract 5 ⁇ 16. 0%, Chuanbei extract 3. 8 ⁇ 15. 8 %, chrysanthemum extract 5 ⁇ 15 5%, Coenzyme Q10 1 ⁇ , 5%, aspartic acid 0. 8 ⁇ 1. 5 %, Coenzyme Q10 1 ⁇ ⁇ 1. 38%, hyaluronic acid 0. 01 ⁇ , 8%, ⁇ / br> ⁇ / br> ⁇ / br> 4. 09%.
- the solvent component is: 35 to 45 parts of propylene glycol, 10 to 15 parts of water; or glycerol 35 to 45 Parts, water 10 to 15 parts.
- the water is pure water or deionized water.
- the curing agent 0. 3 ⁇ 0.
- the curing agent 0. 3 ⁇ 0. 8 parts, propylene glycol or glycerol 10 to 70 parts, water 5 to 25 parts;
- the excipients include the following components: xanthan gum and casein phosphopeptides, their weight ratio in the excipient is 0 . 25 ⁇ 0 67;
- said curing agent comprises the components: fats and propylene glycol alginate date, in which the weight ratio of the curing agent is from 0. 67 25 ⁇ 0.
- the preparation method comprises the following steps: (1) mixing the above components and heating to 85 ° C to 90 ° C to obtain a mixed solution; (2) cooling the mixed solution to -10 ° C to - 20 ° C, a solid electronic aerosolized composition.
- the step (1) is specifically: first adding a curing agent and an excipient to water, mixing uniformly to 85 ° C to 90 ° C until completely dissolved; adding an aqueous solution containing a curing agent and an excipient to propylene glycol or C In the triol, mix well and then heat to 85 ° C ⁇ 90 ° C.
- the cooling device in the step (2) is a refrigerator.
- the solvent component is: 35 to 45 parts of propylene glycol, 10 to 15 parts of water, or 35 to 45 parts of glycerin, and 10 to 15 parts of water.
- the water is pure water or deionized water.
- the composition further comprises the pectin as described above , wherein the curing agent comprises the following components: propylene glycol citrate and sodium alginate, the weight ratio of the curing agent in the curing agent is 0. 25 ⁇ 0; Calcium acid gel 0. 2 ⁇ 1.
- the calcium pectate gel the raw materials including 5 ⁇ 15% of fruit acid, 20 ⁇ 40% of gelatin, 40 ⁇ 60% of water, glycerol 15 ⁇ 20%;
- the fruit acid is one of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid or a combination thereof.
- the preparation method comprises the following steps: preparing a calcium pectate gel by uniformly mixing the fruit acid and the gelatin, water and glycerin in the ratio; (I) the atomized composition group containing the calcium pectate gel described above Mix well and heat to 85 ° C ⁇ 90 °C, a mixed solution; ( ⁇ ) The above mixed solution is cooled to _10 ° C ⁇ - 20 ° C to obtain a solid electronic aerosolized composition.
- the step (I) is specifically: first taking a curing agent, a calcium pectate gel, an excipient into water, mixing uniformly to 85 ° C to 90 ° C until completely dissolved; containing a curing agent, pectin The solution of the calcium acid gel and the excipient is added to propylene glycol or glycerin, mixed uniformly, and then heated to 85 ° C to 90 ° C.
- the cooling device in the step (II) is a refrigerator.
- the solvent component is: 35 to 45 parts of propylene glycol, 10 to 15 parts of water; or 35 to 45 parts of glycerin and 10 to 15 parts of water.
- the water is pure water or deionized water.
- the curing agent 0. 3 ⁇ 0.
- the curing agent 0. 3 ⁇ 0. 8 parts, propylene glycol or glycerol 10 to 70 parts, water 5 to 25 parts;
- the excipients include the following components: xanthan gum and casein phosphopeptides, their weight ratio in the excipient is 0 . 25 ⁇ 0 67;
- said curing agent comprises the components: fats and propylene glycol alginate date, in which the weight ratio of the curing agent is from 0. 67 25 ⁇ 0. 5 ⁇
- the electronic aerosolization composition further comprises 30 ⁇ 35 parts of the medicament, or / and the tobacco extract 3 ⁇ 3. 5 parts, or / and the flavor of the tobacco 3 ⁇ 3.
- the preparation method comprises the following steps: A: adding the curing agent and the excipient to the deionized water according to the above ratio, mixing uniformly and heating to 85 ° C to 90 ° C until completely dissolved to form a mixed solution; B: mixing the solution Add the above ratio of propylene glycol or glycerol, mix well, and then raise the temperature to 85 ° C ⁇ 90 ° C ; C: the final solution in step B is cooled to about 40-75 ° C to add tobacco extract 3 ⁇ 3. 5 parts, or / and tobacco flavor 3 ⁇ 3. 5 parts, or / and 30 ⁇ 35 parts of the drug, mixed evenly; D: the final solution in step C is cooled to ⁇ 10 ° C ⁇ - 20 ° C, A solid electronic aerosolized composition.
- the pharmaceutical agent comprises the following components: Gynostemma pentaphyllum extract, German chamomile extract, casein phosphopeptide, dandelion extract, astragalus extract, honeysuckle extract, Chuanbei extract Liquid, chrysanthemum extract, lily extract, wood butterfly extract, enzyme, aspartic acid, coenzyme Q10, dipotassium glycyrrhizinate, glycyrrhizic acid monoamine, taurine, hyaluronic acid, or a combination thereof, the weight ratio thereof For any ratio.
- Casein phosphopeptide 5 ⁇ 20. 0% the content of the composition of the drug is 25 ⁇ 30. 0%, German chamomile extract 5 ⁇ 20. 0%, casein phosphopeptide 5 ⁇ 20. 0% , dandelion extract 5 ⁇ 15. 0%, scutellaria extract 3 ⁇ 15. 0%, honeysuckle extract 5 ⁇ 16. 0%, Chuanbei extract 3. 8 ⁇ 15. 8 %, chrysanthemum extract 5 ⁇ 15 5%, Coenzyme Q10 1 ⁇ , 5%, aspartic acid 0. 8 ⁇ 1. 5 %, Coenzyme Q10 1 ⁇ ⁇ 1. 38%, hyaluronic acid 0. 01 ⁇ , 8%, ⁇ / br> ⁇ / br> ⁇ / br> 4. 09%.
- the temperature described in step C is 55 °C.
- the cooling device in the step D is a refrigerator.
- the solvent component is: 35 to 45 parts of propylene glycol, 10 to 15 parts of water; or 35 to 45 parts of glycerin and 10 to 15 parts of water.
- the water is pure water or deionized water.
- the curing agent 0. 3 ⁇ 0.
- the curing agent 0. 3 ⁇ 0. 8 parts, propylene glycol or glycerol 10 to 70 parts, water 5 to 25 parts;
- the excipients include the following components: xanthan gum and casein phosphopeptides, their weight ratio in the excipient is 0 . 25 ⁇ 0 67;
- said curing agent comprises the components: fats and propylene glycol alginate date, in which the weight ratio of the curing agent is from 0. 67 25 ⁇ 0.
- the electrospray composition further comprises a calcium pectate gel 0. 2 ⁇ 1. 0 parts, the raw materials including 5 ⁇ 15% of fruit acid, 20 ⁇ 40% of gelatin, 40 ⁇ 70% of water, glycerol 15 ⁇ 20%.
- the electronic aerosolization composition further comprises 30 ⁇ 35 parts of the medicament, or / and the tobacco extract 3 ⁇ 3. 5 parts, or / and the flavor of the tobacco 3 ⁇ 3.
- the preparation method comprises the following steps: 5 ⁇ 15% of fruit acid, 20 ⁇ 40% of gelatin, 40 ⁇ 70% of water, 15 ⁇ 20% of glycerol, uniformly mixed, and heated to 70 ⁇ 90 °C.
- the pharmaceutical agent comprises the following components: Gynostemma pentaphyllum extract, German chamomile extract, casein phosphopeptide, dandelion extract, astragalus extract, honeysuckle extract, Chuanbei extract, chrysanthemum extract, One or a combination of lily extract, wood butterfly extract, enzyme, aspartic acid, coenzyme Q10, dipotassium glycyrrhizinate, glycyrrhizic acid monoamine, taurine, hyaluronic acid, in any ratio.
- Casein phosphopeptide 5 ⁇ 20. 0% the content of the composition of the drug is 25 ⁇ 30. 0%, German chamomile extract 5 ⁇ 20. 0%, casein phosphopeptide 5 ⁇ 20. 0% , dandelion extract 5 ⁇ 15. 0%, scutellaria extract 3 ⁇ : 15. 0%, honeysuckle extract 5 ⁇ 16. 0%, Chuanbei extract 3. 8 ⁇ 15. 8 %, chrysanthemum extract 5 ⁇ 5%, Coenzyme, Coenzyme 0. 8%, Aspartic acid 0. 8 ⁇ 1. 5 %, Coenzyme 8%, ⁇ 0. 1 ⁇ 3. 38%, hyaluronic acid 0 0. 3 ⁇ 3. 8%, taurine 0. 1 ⁇ 3. 38%, hyaluronic acid 0 01 ⁇ 4. 09%.
- the temperature in the step C is 55 °C.
- the device for cooling in step D described therein is a refrigerator.
- the solvent component is: 35 to 45 parts of propylene glycol, 10 to 15 parts of water; or 35 to 45 parts of glycerin and 10 to 15 parts of water. More preferably, the water is pure water or deionized water.
- the invention also provides a calcium pectate gel, the raw material comprising 5 ⁇ 15% of fruit acid, 20 ⁇ 40% of gelatin, 40 ⁇ 70% of water and 15 ⁇ 20% of glycerol.
- the fruit acid described therein is one of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid or a combination thereof.
- the preparation method of the calcium pectate gel taking 5 ⁇ 15% of fruit acid, 20 ⁇ 40% of gelatin, 40 ⁇ 70% of water, 15 ⁇ 20% of glycerol, mixing evenly, and heating to 70 ⁇ 90° C, maintaining the time, the reaction produces a calcium pectate gel.
- the fruit acid is one of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid or a combination thereof.
- the retention time described therein is 1-20 hours.
- the invention also discloses the use of the calcium pectate gel as an atomization stabilizer in an electronic aerosolized composition.
- the medicinal health-care solid electronic atomized composition of the present invention is complicated by a curing agent, an excipient and a solvent (propylene glycol or glycerin, water) due to the use of an excipient, a curing agent, propylene glycol or glycerin.
- the gel reacts and produces a synergistic effect, so that a solid-like gel can be formed which is much more convenient for the user than the liquid atomized composition.
- the addition of a calcium pectate gel to the composition enables the atomized composition to form a network-like microcapsule structure, so that the atomized droplet size distribution is more uniform and finer, compared to the original atomization. Liquid, a greatly increased aerosol stability upon atomization.
- the excipients are 3.0 parts, the curing agent is 0.8 parts, the propylene glycol is 60 parts, and the deionized water is 20 parts; the excipient consists of: xanthan gum and casein phosphopeptide, which are in the excipient
- the weight ratio is 0.5, that is, 1 part of xanthan gum, 2 parts of casein phosphopeptide (of course, other components may be included in other embodiments);
- the curing agent includes the following components: Acid propylene glycol ester and sodium alginate, they are solid 2 ⁇ Sodium alginate 0. 6 ⁇ The weight ratio of 0. 33, that is, propylene glycol methacrylate 0. 2 parts, sodium alginate 0. 6 parts.
- the composition of the medicinal health-type solid electronic atomization composition comprising: propylene glycol 60 parts, deionized water 20 parts, excipients 3. 0 parts, curing agent 0. 8 parts, calcium pectate gel 1. 0 5 ⁇ ,
- the tobacco extract is a liquid-type cloud smoke extract, a tobacco flavor 3. 5 parts, is a rose essence, a medicament 33. 2 parts.
- the medicinal composition of the ginseng extract is 10. 0%, the casein phosphopeptide 1.0. 0%, the dandelion extract 8. 0%, the scutellaria extract 8. 0%, the honeysuckle extract 6. 0%,1,5 %, Aspartic acid 1. 5 %, ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 %%, the total amount of the coenzyme Q10 1. 33%, dipotassium glycyrrhizinate 1. 0%, glycyrrhizic acid monoamine 0. 8%, taurine 0. 38%, hyaluronic acid 0. 09%, their total amount is 33. 2 servings.
- Medicinal health-type solid electronic atomization composition the main composition is: propylene glycol 45 parts, 35 parts of medicament, is a Gynostemma extract 30. 0, deionized water 10. 0 parts, the remaining components and preparation method is the same as in the second embodiment , Gynostemma-type electronic aerosolized cream. Can maintain a solid paste, easy to use, stable atomization
- the medicinal health-type solid electronic atomization composition is: propylene glycol, 42 parts, 32 parts of the medicament, is a solution of Gynostemma pentaphyllum 32.0 parts, deionized water 15.0 parts, the remaining components and preparation method and Example 2
- the Gynostemma-type electronic aerosolized paste can maintain a solid paste shape, is convenient to use, and has stable atomization.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
An electronic cigarette's atomization composition comprises the following components by weight parts: 2-3.0 parts of an excipient, 0.3-0.8 part of a curing agent, 10-70 parts of propylene glycol or glycerol, and 5-25 parts of water; the excipient comprises the following components: xanthan gum and casein phosphopeptide in a weight ratio of 0.25-0.67; the curing agent comprises the following components: propylene glycol alginate and sodium alginate in a weight ratio of 0.25-0.67, wherein propylene glycol or glycerol and water are solvents. In a calcium pectate gel and preparation process and use thereof, the calcium pectate gel comprises 5-15% of fruit acid, 20-40% of gelatin, 40-70% of water, and 15-20% of glycerol. The electronic cigarette's atomization composition can be maintained as a solid paste, so it is convenient to use, and has stable atomization effects.
Description
说 明 书 电子烟雾化组合物与果胶酸钙凝胶及其制备方法和应用 技术领域 Description Electronic aerosolized composition and calcium pectate gel, and preparation method and application thereof
本发明涉及一种电子烟雾化组合物及制备方法, 同时也涉及一种果胶酸钙 凝胶及其制备方法和应用。 The invention relates to an electronic aerosolization composition and a preparation method thereof, and also relates to a calcium pectate gel and a preparation method and application thereof.
背景技术 Background technique
目前, 市场上出现了很多的香烟替代品, 其中以电子香烟最为常见, 这种 电子香烟通常用液体的雾化液来进行雾化, 产生烟雾效果。 电子烟雾化液也俗 称 "烟油"。 At present, there are many cigarette substitutes on the market, among which electronic cigarettes are most common. Such electronic cigarettes are usually atomized by liquid atomized liquid to produce a smoke effect. Electronic aerosolization liquid is also commonly known as "smoke oil".
电子香烟的结构中一般包括一个雾化器。 传统电子香烟往往把雾化器和烟 嘴部分粘合起来, 做成一次性雾化器。 现有技术的雾化器的构造就是一个升温 元器件, 通过电池供电发热, 使其旁边的烟油挥发, 形成烟雾, 从而让人吸的 时候达到 "吞云吐雾"的效果。 The structure of an electronic cigarette generally includes an atomizer. Conventional electronic cigarettes often bond the atomizer to the mouthpiece to make a disposable atomizer. The structure of the prior art atomizer is a temperature-increasing component, which is heated by a battery to cause the smoke oil adjacent to it to volatilize, forming a smoke, thereby achieving the effect of "swallowing clouds and spitting" when sucking.
因此, 在电子香烟的使用中, 需要有不断添加的电子烟雾化液。 因为其通 常含有烟叶提取物, 也称之为烟油。 中国发明专利申请公布说明书 (公开号 CN 101461566A; 公开日: 2009年 6月 24日)公开了一种电子香烟雾化液, 其在摘 要中论述道: "其主要组成为: 烟叶提取物 3丙二醇 50〜70%w/v,纯水 5〜 10%w ,烟用香精 3〜5%w/v,烟碱 0〜3%w/v,稳定剂 0. 2〜: L%w/v和增稠剂 3 v, 另外还含有磷酸可待因、 麻黄素、 愈创木酚甘油醚、 扑尔敏、 海恩流浸膏及糖 浆等, 因为它无二手烟的危害, 故在公共场合也完全可以用, 不会影响它人健 康; 可在享受吞烟吐雾的同时, 又可治疗因伤风、 流行性感冒及类似的上呼吸 道感染所引起的咳嗽、 干咳、 喉咙痕痒、 痰多、 敏感性咳嗽等"。
然而, 上述的电子烟雾化液大多是液体产品, 需要预先灌装或者。 毕竟, 液体产品的使用相比于固态产品, 运输时比较麻烦。 同时, 使用也不够方便, 经常会产生液体倒吸、 香气挥发快、 泄漏等问题。 Therefore, in the use of electronic cigarettes, it is necessary to have an electronic aerosolizing liquid that is continuously added. Because it usually contains tobacco leaf extract, it is also called smoke oil. The Chinese invention patent application publication specification (publication number CN 101461566A; publication date: June 24, 2009) discloses an electronic cigarette atomization liquid, which is discussed in the abstract: "The main components are: tobacco leaf extract 3 propylene glycol 50~70%w/v, pure water 5~10%w, tobacco flavor 3~5%w/v, nicotine 0~3%w/v, stabilizer 0. 2~: L%w/v and Thickener 3 v, also contains codeine phosphate, ephedrine, guaiacol glyceryl ether, chlorpheniramine, haien extract and syrup, because it has no second-hand smoke, so it is also used in public places. It can be used completely without affecting its health; it can also treat cough, dry cough, itchy throat and phlegm caused by colds, influenza and similar upper respiratory tract infections while enjoying the smoke and vomiting. Sensitive cough, etc.". However, the above-mentioned electronic aerosolization liquid is mostly a liquid product and needs to be prefilled or. After all, the use of liquid products is more troublesome when transporting than solid products. At the same time, it is not convenient to use, and often causes problems such as liquid sucking, aroma evaporation, and leakage.
发明内容 Summary of the invention
针对上述技术的缺陷, 本发明要解决的技术问题就是要提供一种能保持固 态膏状的电子烟雾化组合物及其制备方法。 同时, 本发明还提供一种使雾化效 果更稳定的果胶酸钙凝胶及其制备方法和应用。 In view of the deficiencies of the above techniques, the technical problem to be solved by the present invention is to provide an electronic aerosolized composition capable of maintaining a solid paste and a preparation method thereof. At the same time, the present invention also provides a calcium pectate gel which makes the atomization effect more stable, and a preparation method and application thereof.
具体技术方案如下。 The specific technical solutions are as follows.
在没有特别说明的情况下, 本发明中所提到的比例皆为重量比例。 The ratios mentioned in the present invention are all by weight unless otherwise specified.
一种电子烟雾化组合物, 其包括重量比的如下组份: 赋形剂 2〜3. 0份、 固 化剂 0. 3〜0. 8份、 丙二醇或丙三醇 10〜70份、 水 5〜25份。 较好的, 所述的 丙二醇或丙三醇是市售的产品。 其中, 丙二醇或丙三醇、 水是溶剂, 也就是本 发明的溶剂为三种, 一种是丙二醇和水的混合物, 一种是丙三醇和水的混合物, 一种是丙二醇、 丙三醇、 水的混合物。 但是, 本发明的计量是丙二醇和丙三醇 混合在一起计量的。 较好的情况下, 不采用丙二醇、 丙三醇、 水的混合物的溶 剂方案。 An electronic aerosol composition comprising the following components in a weight ratio: excipient 2~3. 0 parts, curing agent 0. 3~0. 8 parts, propylene glycol or glycerol 10~70 parts, water 5 ~25 copies. Preferably, the propylene glycol or glycerol is a commercially available product. Wherein, propylene glycol or glycerol, water is a solvent, that is, the solvent of the present invention is three kinds, one is a mixture of propylene glycol and water, one is a mixture of glycerin and water, and the other is propylene glycol, glycerin, a mixture of water. However, the metering of the present invention is measured by mixing together propylene glycol and glycerol. Preferably, a solvent solution of a mixture of propylene glycol, glycerol, and water is not employed.
所述的赋形剂包括如下组份: 黄原胶和酪蛋白磷酸肽, 它们在赋形剂中的 重量比例为 0. 25〜0. 67。 较好的, 黄原胶和酪蛋白磷酸肽是市售的产品, 具有 增稠和粘合的作用。 所述的固化剂包括下组份: 枣酸丙二醇脂和海藻酸钠, 它 们在固化剂中的重量比例为 0. 25〜0. 67。 较好的, 枣酸丙二醇脂和海藻酸钠选 用市售的产品。 因为赋形剂和固化剂的存在, 可以使电子烟雾化组合物形成固 态的膏状物质, 类似于牙膏。
所述的组合物,其还包括重量比的如下组份:所述的果胶酸钙凝胶 0. 2〜1. 0 份。 这个份数是基于电子烟雾化组合物的总体组分来计算的。 所述的果胶酸钙 凝胶, 其原料包括果酸 5〜15%、 明胶 20〜40%、 水 40〜60%、 丙三醇 15〜20%。 所述的果酸, 是甘醇酸、 乳酸、 苹果酸、 酒石酸、 柠檬酸、 杏仁酸之一或其组 合。 果胶酸钙凝胶在电子烟雾化组合物的作用是增强其雾化时的稳定性。 需要 注意的是, 在没有特别说明的情况下, 本发明说明书中的份数都是基于电子烟 雾化组合物的总体组分来计算的。 5〜0. 67。 The excipient comprising the following components: xanthan gum and casein phosphopeptides, the weight ratio of the excipient is 0. 25~0. 67. Preferably, xanthan gum and casein phosphopeptides are commercially available products having thickening and binding effects. 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。. Preferably, propylene glycol citrate and sodium alginate are commercially available products. Because of the presence of excipients and curing agents, the electronic aerosolizing composition can be formed into a solid, creamy substance, similar to a toothpaste. 5份。 The composition of the composition of the weight ratio of the following components: the calcium pectate gel 0. 2~1. 0 parts. This fraction is calculated based on the overall composition of the electronic aerosolized composition. The calcium pectate gel has a raw material comprising 5 to 15% of fruit acid, 20 to 40% of gelatin, 40 to 60% of water, and 15 to 20% of glycerin. The fruit acid is one of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid or a combination thereof. The role of the calcium pectate gel in the electronic aerosolization composition is to enhance its stability upon atomization. It is to be noted that the parts in the specification of the present invention are calculated based on the overall composition of the electronic aerosolized composition, unless otherwise specified.
所述的组合物, 其还包括重量比的如下组份: 药剂 30〜35份, 或者 /和烟 草提取液 3〜3. 5份,或者 /和烟用香精 3〜3. 5份。所述的烟草提取液,较好的, 是市售的烟草提取液, 更好的, 是烟草浸膏, 例如云烟浸膏。 所述烟用香精, 较好的, 是通常市售的香精。 5份。 The composition further comprising the following components by weight: 30~35 parts of the medicament, or / and the tobacco extract 3~3. 5 parts, or / and the flavor of the tobacco 3~3. Preferably, the tobacco extract is a commercially available tobacco extract, more preferably a tobacco extract, such as a cloud smoke extract. The tobacco flavor, preferably, is a commercially available flavor.
所述的药剂的包括如下组份: 绞股蓝萃取液、 德国洋甘菊萃取液、 酪蛋白 磷酸肽、 蒲公英萃取液、 黄芪萃取液、 金银花萃取液、 川贝萃取液、 菊花萃取 液、 百合萃取液、 木蝴蝶萃取液、 酵素、 天门冬氨酸、 辅酶 Q10、 甘草酸二钾、 甘草酸单胺、 牛磺酸、 透明质酸之一或组合。 由于药剂属于辅剂, 其各种组分 的重量比可以为任意比例。 上述药剂就是市售的药剂。 The medicament comprises the following components: Gynostemma extract, German chamomile extract, casein phosphopeptide, dandelion extract, astragalus extract, honeysuckle extract, Chuanbei extract, chrysanthemum extract, lily extract, wood One or a combination of butterfly extract, enzyme, aspartic acid, coenzyme Q10, dipotassium glycyrrhizinate, glycyrrhizic acid monoamine, taurine, hyaluronic acid. Since the agent is an adjuvant, the weight ratio of the various components can be any ratio. The above agents are commercially available agents.
较好的, 所述的药剂中组份占药剂的重量百分比为: 绞股蓝萃取液 25〜 30. 0%、德国洋甘菊萃取液 5〜20. 0%、酪蛋白磷酸肽 5〜20. 0%、蒲公英萃取液 5〜 15. 0%、黄芪萃取液 3〜: 15. 0%、金银花萃取液 5〜 16. 0%、川贝萃取液 3. 8〜15. 8 %、 菊花萃取液 5〜15. 6 %、 百合萃取液 4〜15. 0%、 木蝴蝶萃取液 4〜5. 0%、 酵 素 1〜1. 5 %、 天门冬氨酸 0. 8〜1. 5 %、 辅酶 Q10 1〜4. 33 %、 甘草酸二钾 0. 8〜 5. 0%、 甘草酸单胺 0. 5〜3. 8%、 牛磺酸 0. 1〜3. 38%、 透明质酸 0. 01〜4. 09%。 Preferably, the composition of the drug in the weight percentage of the drug is: Gynostemma pentaphyllum extract 25~ 30. 0%, German chamomile extract 5~20. 0%, casein phosphopeptide 5~20. 0%, Dandelion extract 5~ 15. 0%, Astragalus extract 3~: 15. 0%, honeysuckle extract 5~ 16. 0%, Chuanbei extract 3. 8~15. 8 %, chrysanthemum extract 5~15 5%, Coenzyme Q10 1~, 5%, aspartic acid 0. 8~1. 5 %, Coenzyme Q10 1~ 〜1. 38%, hyaluronic acid 0. 01~, 8%, </ br> </ br> </ br> </ br> 4. 09%.
所述的溶剂组份为: 丙二醇 35〜45份、 水 10〜15份; 或者丙三醇 35〜45
份、 水 10〜15份。 较好的, 所述的水为纯净水或者去离子水。 The solvent component is: 35 to 45 parts of propylene glycol, 10 to 15 parts of water; or glycerol 35 to 45 Parts, water 10 to 15 parts. Preferably, the water is pure water or deionized water.
同时, 本发明还公开了所述的电子烟雾化组合物的制备方法, 当电子烟雾 化组合物包括有以下组分时: 赋形剂 2〜3. 0份、 固化剂 0. 3〜0. 8份、 丙二醇 或丙三醇 10〜70份、 水 5〜25份; 所述的赋形剂包括如下组份: 黄原胶和酪蛋 白磷酸肽, 它们在赋形剂中的重量比例为 0. 25〜0. 67; 所述的固化剂包括下组 份: 枣酸丙二醇脂和海藻酸钠, 它们在固化剂中的重量比例为 0. 25〜0. 67。 00. 0. 3〜0. The curing agent 0. 3~0. The curing agent 0. 3~0. 8 parts, propylene glycol or glycerol 10 to 70 parts, water 5 to 25 parts; the excipients include the following components: xanthan gum and casein phosphopeptides, their weight ratio in the excipient is 0 . 25~0 67; said curing agent comprises the components: fats and propylene glycol alginate date, in which the weight ratio of the curing agent is from 0. 67 25~0.
这种制备方法的包括如下步骤: (1 ) 按上述组份混合均勾并升温至 85°C〜 90°C, 得混合溶液; (2 ) 上述混合溶液降温至 -10°C〜- 20°C, 得固态的电子烟 雾化组合物。 较好的, 步骤(1 )具体为: 先取固化剂、 赋形剂加入水中, 混合 均匀到 85°C〜90°C至完全溶解; 将含固化剂、 赋形剂的水溶液加入到丙二醇或 者丙三醇中, 混合均匀, 再升温到 85°C〜90°C。所述的步骤(2) 中的降温的设 备为冷柜。 所述的溶剂组份为: 丙二醇 35〜45份、 水 10〜15份, 或者丙三醇 35〜45份、 水 10〜15份。 较好的, 所述的水为纯净水或者去离子水。 The preparation method comprises the following steps: (1) mixing the above components and heating to 85 ° C to 90 ° C to obtain a mixed solution; (2) cooling the mixed solution to -10 ° C to - 20 ° C, a solid electronic aerosolized composition. Preferably, the step (1) is specifically: first adding a curing agent and an excipient to water, mixing uniformly to 85 ° C to 90 ° C until completely dissolved; adding an aqueous solution containing a curing agent and an excipient to propylene glycol or C In the triol, mix well and then heat to 85 ° C ~ 90 ° C. The cooling device in the step (2) is a refrigerator. The solvent component is: 35 to 45 parts of propylene glycol, 10 to 15 parts of water, or 35 to 45 parts of glycerin, and 10 to 15 parts of water. Preferably, the water is pure water or deionized water.
同时, 本发明还公开了所述的电子烟雾化组合物的制备方法, 当电子烟雾 化组合物包括有以下组分时: 赋形剂 2〜3. 0份、 固化剂 0. 3〜0. 8份、 丙二醇 或丙三醇 10〜70份、 水 5〜25份; 所述的赋形剂包括如下组份: 黄原胶和酪蛋 白磷酸肽, 它们在赋形剂中的重量比例为 0. 25〜0. 67; 所述的固化剂包括下组 份: 枣酸丙二醇脂和海藻酸钠, 它们在固化剂中的重量比例为 0. 25〜0; 组合物 还包括所述的果胶酸钙凝胶 0. 2〜1. 0份, 所述的果胶酸钙凝胶, 其原料包括果 酸 5〜15%、 明胶 20〜40%、 水 40〜60%、 丙三醇 15〜20%; 所述的果酸, 是甘醇 酸、 乳酸、 苹果酸、 酒石酸、 柠檬酸、 杏仁酸之一或其组合。 其制备方法包括 如下步骤: 按所述比例的果酸和明胶、 水、 丙三醇均匀混合制备果胶酸钙凝胶; ( I ) 按上述含果胶酸钙凝胶的雾化组合物组份, 混合均匀并升温至 85°C〜90
°C, 得混合溶液; (Π )上述混合溶液降温至 _10°C〜- 20°C, 得固态电子烟雾化 组合物。 00. 0. 3〜0. The curing agent 0. 3~0. The curing agent 0. 3~0. 8 parts, propylene glycol or glycerol 10 to 70 parts, water 5 to 25 parts; the excipients include the following components: xanthan gum and casein phosphopeptides, their weight ratio in the excipient is 0 The composition further comprises the pectin as described above , wherein the curing agent comprises the following components: propylene glycol citrate and sodium alginate, the weight ratio of the curing agent in the curing agent is 0. 25~0; Calcium acid gel 0. 2~1. 0 parts, the calcium pectate gel, the raw materials including 5~15% of fruit acid, 20~40% of gelatin, 40~60% of water, glycerol 15~ 20%; the fruit acid is one of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid or a combination thereof. The preparation method comprises the following steps: preparing a calcium pectate gel by uniformly mixing the fruit acid and the gelatin, water and glycerin in the ratio; (I) the atomized composition group containing the calcium pectate gel described above Mix well and heat to 85 ° C ~ 90 °C, a mixed solution; (Π) The above mixed solution is cooled to _10 ° C ~ - 20 ° C to obtain a solid electronic aerosolized composition.
较好的, 其中步骤 ( I ) 具体为: 先取固化剂、 果胶酸钙凝胶、 赋形剂加 入水中, 混合均匀到 85°C〜90°C至完全溶解; 将含固化剂、 果胶酸钙凝胶、 赋 形剂的溶液加入到丙二醇或者丙三醇中, 混合均匀, 再升温到 85°C〜90°C。 Preferably, the step (I) is specifically: first taking a curing agent, a calcium pectate gel, an excipient into water, mixing uniformly to 85 ° C to 90 ° C until completely dissolved; containing a curing agent, pectin The solution of the calcium acid gel and the excipient is added to propylene glycol or glycerin, mixed uniformly, and then heated to 85 ° C to 90 ° C.
较好的, 其中所述的步骤 (II ) 中的降温的设备为冷柜。 其中所述的溶剂 组份为: 丙二醇 35〜45份、 水 10〜15份; 或者丙三醇 35〜45份、 水 10〜15 份。 较好的, 其中所述的水为纯净水或者去离子水。 Preferably, the cooling device in the step (II) is a refrigerator. The solvent component is: 35 to 45 parts of propylene glycol, 10 to 15 parts of water; or 35 to 45 parts of glycerin and 10 to 15 parts of water. Preferably, the water is pure water or deionized water.
同时, 本发明还公开了所述的电子烟雾化组合物的制备方法, 当电子烟雾 化组合物包括有以下组分时: 赋形剂 2〜3. 0份、 固化剂 0. 3〜0. 8份、 丙二醇 或丙三醇 10〜70份、 水 5〜25份; 所述的赋形剂包括如下组份: 黄原胶和酪蛋 白磷酸肽, 它们在赋形剂中的重量比例为 0. 25〜0. 67; 所述的固化剂包括下组 份: 枣酸丙二醇脂和海藻酸钠, 它们在固化剂中的重量比例为 0. 25〜0. 67。 所 述的电子烟雾化组合物还包括药剂 30〜35份, 或者 /和烟草提取液 3〜3. 5份, 或者 /和烟用香精 3〜3. 5份。 00. 0. 3〜0. The curing agent 0. 3~0. The curing agent 0. 3~0. 8 parts, propylene glycol or glycerol 10 to 70 parts, water 5 to 25 parts; the excipients include the following components: xanthan gum and casein phosphopeptides, their weight ratio in the excipient is 0 . 25~0 67; said curing agent comprises the components: fats and propylene glycol alginate date, in which the weight ratio of the curing agent is from 0. 67 25~0. 5份。 The electronic aerosolization composition further comprises 30~35 parts of the medicament, or / and the tobacco extract 3~3. 5 parts, or / and the flavor of the tobacco 3~3.
其制备方法, 包括如下步骤: A: 按上述比例取固化剂、 赋形剂加入去离子 水中, 混合均匀并升温到 85°C〜90°C至完全溶解, 形成混合溶液; B:将混合溶 液加入上述比例的丙二醇或丙三醇中, 混合均匀, 再升温到 85°C〜90°C ; C:将 步骤 B中最终的溶液降温至 40-75°C左右加入烟草提取液 3〜3. 5份,或 /和烟用 香精 3〜3. 5份, 或 /和药剂 30〜35份, 混合均匀; D:将步骤 C中最终的溶液降 温至〜 10°C〜- 20°C, 得到固体的电子烟雾化组合物。 The preparation method comprises the following steps: A: adding the curing agent and the excipient to the deionized water according to the above ratio, mixing uniformly and heating to 85 ° C to 90 ° C until completely dissolved to form a mixed solution; B: mixing the solution Add the above ratio of propylene glycol or glycerol, mix well, and then raise the temperature to 85 ° C ~ 90 ° C ; C: the final solution in step B is cooled to about 40-75 ° C to add tobacco extract 3~3. 5 parts, or / and tobacco flavor 3~3. 5 parts, or / and 30~35 parts of the drug, mixed evenly; D: the final solution in step C is cooled to ~ 10 ° C ~ - 20 ° C, A solid electronic aerosolized composition.
较好的, 其中所述的药剂的包括如下组份: 绞股蓝萃取液、 德国洋甘菊萃 取液、 酪蛋白磷酸肽、 蒲公英萃取液、 黄芪萃取液、 金银花萃取液、 川贝萃取
液、 菊花萃取液、 百合萃取液、 木蝴蝶萃取液、 酵素、 天门冬氨酸、 辅酶 Q10、 甘草酸二钾、 甘草酸单胺、 牛磺酸、 透明质酸之一或组合, 其重量比为任意比 例。 Preferably, the pharmaceutical agent comprises the following components: Gynostemma pentaphyllum extract, German chamomile extract, casein phosphopeptide, dandelion extract, astragalus extract, honeysuckle extract, Chuanbei extract Liquid, chrysanthemum extract, lily extract, wood butterfly extract, enzyme, aspartic acid, coenzyme Q10, dipotassium glycyrrhizinate, glycyrrhizic acid monoamine, taurine, hyaluronic acid, or a combination thereof, the weight ratio thereof For any ratio.
更好的,其中所述的药剂的组份占药剂的重量百分比为:绞股蓝萃取液 25〜 30. 0%、德国洋甘菊萃取液 5〜20. 0%、酪蛋白磷酸肽 5〜20. 0%、蒲公英萃取液 5〜 15. 0%、黄芪萃取液 3〜15. 0%、金银花萃取液 5〜 16. 0%、川贝萃取液 3. 8〜15. 8 %、 菊花萃取液 5〜15. 6 %、 百合萃取液 4〜15. 0%、 木蝴蝶萃取液 4〜5. 0%、 酵 素 1〜1. 5 %、 天门冬氨酸 0. 8〜1. 5 %、 辅酶 Q10 1〜4. 33 %、 甘草酸二钾 0. 8〜 5. 0%、 甘草酸单胺 0. 5〜3. 8%、 牛磺酸 0. 1〜3. 38%、 透明质酸 0. 01〜4. 09%。 0%。 Casein phosphopeptide 5~20. 0%, the content of the composition of the drug is 25~ 30. 0%, German chamomile extract 5~20. 0%, casein phosphopeptide 5~20. 0% , dandelion extract 5~15. 0%, scutellaria extract 3~15. 0%, honeysuckle extract 5~ 16. 0%, Chuanbei extract 3. 8~15. 8 %, chrysanthemum extract 5~15 5%, Coenzyme Q10 1~, 5%, aspartic acid 0. 8~1. 5 %, Coenzyme Q10 1~ 〜1. 38%, hyaluronic acid 0. 01~, 8%, </ br> </ br> </ br> </ br> 4. 09%.
较好的, 其中步骤 C中所述的温度为 55°C。 较好的, 所述的步骤 D中的降 温的设备为冷柜。 较好的, 其中所述的溶剂组份为: 丙二醇 35〜45份、 水 10〜 15份; 或者丙三醇 35〜45份、 水 10〜15份。 较好的, 其中所述的水为纯净水 或者去离子水。 Preferably, the temperature described in step C is 55 °C. Preferably, the cooling device in the step D is a refrigerator. Preferably, the solvent component is: 35 to 45 parts of propylene glycol, 10 to 15 parts of water; or 35 to 45 parts of glycerin and 10 to 15 parts of water. Preferably, the water is pure water or deionized water.
同时, 本发明还公开了所述的电子烟雾化组合物的制备方法, 当电子烟雾 化组合物包括有以下组分时: 赋形剂 2〜3. 0份、 固化剂 0. 3〜0. 8份、 丙二醇 或丙三醇 10〜70份、 水 5〜25份; 所述的赋形剂包括如下组份: 黄原胶和酪蛋 白磷酸肽, 它们在赋形剂中的重量比例为 0. 25〜0. 67; 所述的固化剂包括下组 份: 枣酸丙二醇脂和海藻酸钠, 它们在固化剂中的重量比例为 0. 25〜0. 67。 00. 0. 3〜0. The curing agent 0. 3~0. The curing agent 0. 3~0. 8 parts, propylene glycol or glycerol 10 to 70 parts, water 5 to 25 parts; the excipients include the following components: xanthan gum and casein phosphopeptides, their weight ratio in the excipient is 0 . 25~0 67; said curing agent comprises the components: fats and propylene glycol alginate date, in which the weight ratio of the curing agent is from 0. 67 25~0.
所述的电子烟雾化组合物还包括果胶酸钙凝胶 0. 2〜1. 0份, 其原料包括果 酸 5〜15%、 明胶 20〜40%、 水 40〜70%、 丙三醇 15〜20%。 The electrospray composition further comprises a calcium pectate gel 0. 2~1. 0 parts, the raw materials including 5~15% of fruit acid, 20~40% of gelatin, 40~70% of water, glycerol 15~20%.
所述的电子烟雾化组合物还包括药剂 30〜35份,或者 /和烟草提取液 3〜3. 5 份, 或者 /和烟用香精 3〜3. 5份。
其制备方法, 包括如下步骤: 按上述比例的果酸 5〜15%、 明胶 20〜40%、 水 40〜70%、 丙三醇 15〜20%, 混合均匀, 升温至 70〜90°C, 保持时间, 反应制 备果胶酸钙凝胶; A: 按上述比例取固化剂、 果胶酸钙凝胶、 赋形剂加入去离子 水中, 混合均匀并升温至 85'C〜90°C至完全溶解, 形成混合溶液; B:将混合溶 液加入到上述比例的丙二醇或丙三醇中, 混合均匀, 再升温到 85°C〜90°C ; C: 将步骤 B中最终的溶液降温至 40-75°C左右加入烟草提取液 3〜3. 5份,或 /和烟 用香精 3〜3. 5份, 或 /和药剂 30〜35份, 混合均匀; D:将步骤 C中最终的溶液 降温至〜 10 °C〜- 20 °C, 得到固体的电子烟雾化组合物。 5份。 The electronic aerosolization composition further comprises 30~35 parts of the medicament, or / and the tobacco extract 3~3. 5 parts, or / and the flavor of the tobacco 3~3. The preparation method comprises the following steps: 5~15% of fruit acid, 20~40% of gelatin, 40~70% of water, 15~20% of glycerol, uniformly mixed, and heated to 70~90 °C. Hold the time, react to prepare calcium pectate gel; A: Take the curing agent, calcium pectate gel, excipients into deionized water according to the above ratio, mix well and raise the temperature to 85'C~90 °C to complete Dissolve to form a mixed solution; B: Add the mixed solution to the above ratio of propylene glycol or glycerin, mix well, and then raise the temperature to 85 ° C ~ 90 ° C; C: cool the final solution in step B to 40 - Adding tobacco extract 3~3. 5 parts, or / and tobacco flavor 3~3. 5 parts, or / and 30~35 parts of the medicament, mixing evenly; D: cooling the final solution in step C To ~10 °C ~ - 20 °C, a solid electronic aerosolized composition is obtained.
较好的, 其中所述的药剂的包括如下组份: 绞股蓝萃取液、 德国洋甘菊萃 取液、 酪蛋白磷酸肽、 蒲公英萃取液、 黄芪萃取液、 金银花萃取液、 川贝萃取 液、 菊花萃取液、 百合萃取液、 木蝴蝶萃取液、 酵素、 天门冬氨酸、 辅酶 Q10、 甘草酸二钾、 甘草酸单胺、 牛磺酸、 透明质酸之一或组合, 其重量比为任意比 例。 Preferably, the pharmaceutical agent comprises the following components: Gynostemma pentaphyllum extract, German chamomile extract, casein phosphopeptide, dandelion extract, astragalus extract, honeysuckle extract, Chuanbei extract, chrysanthemum extract, One or a combination of lily extract, wood butterfly extract, enzyme, aspartic acid, coenzyme Q10, dipotassium glycyrrhizinate, glycyrrhizic acid monoamine, taurine, hyaluronic acid, in any ratio.
更好的,其中所述的药剂的组份占药剂的重量百分比为:绞股蓝萃取液 25〜 30. 0%、德国洋甘菊萃取液 5〜20. 0%、酪蛋白磷酸肽 5〜20. 0%、蒲公英萃取液 5〜 15. 0%、黄芪萃取液 3〜: 15. 0%、金银花萃取液 5〜 16. 0%、川贝萃取液 3. 8〜15. 8 %、 菊花萃取液 5〜15. 6 %、 百合萃取液 4〜; 15. 0%、 木蝴蝶萃取液 4〜5. 0%、 酵 素 1〜: 1. 5 %、 天门冬氨酸 0. 8〜1. 5 %、 辅酶 Q10 1〜4. 33 %、 甘草酸二钾 0. 8〜 5. 0%、 甘草酸单胺 0. 5〜3. 8%、 牛磺酸 0. 1〜3. 38%、 透明质酸 0. 01〜4. 09%。 0%。 Casein phosphopeptide 5~20. 0%, the content of the composition of the drug is 25~ 30. 0%, German chamomile extract 5~20. 0%, casein phosphopeptide 5~20. 0% , dandelion extract 5~ 15. 0%, scutellaria extract 3~: 15. 0%, honeysuckle extract 5~ 16. 0%, Chuanbei extract 3. 8~15. 8 %, chrysanthemum extract 5~ 5%, Coenzyme, Coenzyme 0. 8%, Aspartic acid 0. 8~1. 5 %, Coenzyme 8%, 酸酸酸0. 1〜3. 38%, hyaluronic acid 0 0. 3~3. 8%, taurine 0. 1~3. 38%, hyaluronic acid 0 01~4. 09%.
较好的, 其中所述的步骤 C中的温度为 55°C。 其中所述的步骤 D中的降温 的设备为冷柜。 较好的, 所述的溶剂组份为: 丙二醇 35〜45份、 水 10〜15份; 或者丙三醇 35〜45份、 水 10〜15份。 更好的, 其中所述的水为纯净水或者去 离子水。
本发明还提供一种果胶酸钙凝胶, 其原料包括果酸 5〜15%、 明胶 20〜40%、 水 40〜70%、 丙三醇 15〜20%。 其中所述的果酸, 是甘醇酸、 乳酸、 苹果酸、 酒 石酸、 柠檬酸、 杏仁酸之一或其组合。 Preferably, the temperature in the step C is 55 °C. The device for cooling in step D described therein is a refrigerator. Preferably, the solvent component is: 35 to 45 parts of propylene glycol, 10 to 15 parts of water; or 35 to 45 parts of glycerin and 10 to 15 parts of water. More preferably, the water is pure water or deionized water. The invention also provides a calcium pectate gel, the raw material comprising 5~15% of fruit acid, 20~40% of gelatin, 40~70% of water and 15~20% of glycerol. The fruit acid described therein is one of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid or a combination thereof.
所述的果胶酸钙凝胶的制备方法: 取果酸 5〜15%、 明胶 20〜40%、 水 40〜 70%、 丙三醇 15〜20%, 混合均匀, 升温至 70〜90°C, 保持时间, 反应制得果胶 酸钙凝胶。 所述的果酸, 是甘醇酸、 乳酸、 苹果酸、 酒石酸、 柠檬酸、 杏仁酸 之一或其组合。 其中所述的保持时间为 1-20小时。 The preparation method of the calcium pectate gel: taking 5~15% of fruit acid, 20~40% of gelatin, 40~70% of water, 15~20% of glycerol, mixing evenly, and heating to 70~90° C, maintaining the time, the reaction produces a calcium pectate gel. The fruit acid is one of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid or a combination thereof. The retention time described therein is 1-20 hours.
本发明还公开了所述的果胶酸钙凝胶在电子烟雾化组合物中作为雾化稳定 剂的应用。 The invention also discloses the use of the calcium pectate gel as an atomization stabilizer in an electronic aerosolized composition.
本发明的药用保健型固体电子雾化组合物由于采用赋形剂、 固化剂、 丙二 醇或丙三醇, 由于固化剂、 赋形剂与溶剂 (丙二醇或丙三醇、 水) 发生了复杂 的凝胶反应, 并产生协同效应, 因此可以形成类似于固态的凝胶, 相比较于液 体雾化组合物, 大大方便了使用者。 而组分中添加了果胶酸钙凝胶, 能够使雾 化组合物形成网络状的微囊结构, 使雾化的微小液滴粒径分布更均匀和细腻, 相比较于原有的雾化液, 大幅增加的雾化时气溶胶的稳定性。 The medicinal health-care solid electronic atomized composition of the present invention is complicated by a curing agent, an excipient and a solvent (propylene glycol or glycerin, water) due to the use of an excipient, a curing agent, propylene glycol or glycerin. The gel reacts and produces a synergistic effect, so that a solid-like gel can be formed which is much more convenient for the user than the liquid atomized composition. The addition of a calcium pectate gel to the composition enables the atomized composition to form a network-like microcapsule structure, so that the atomized droplet size distribution is more uniform and finer, compared to the original atomization. Liquid, a greatly increased aerosol stability upon atomization.
具体实施方式 detailed description
下面结合结合实施例对本发明作进一步说明。 The invention will be further described below in conjunction with the embodiments.
实施例 1 Example 1
赋形剂 3. 0份、 固化剂 0. 8份、 丙二醇 60份、 去离子水 20份; 所述的赋 形剂由: 黄原胶和酪蛋白磷酸肽组成, 它们在赋形剂中的重量比例为 0. 5, 也就 是黄原胶 1份, 酪蛋白磷酸肽 2份 (当然, 在另外一些实施例中也可以包括其 它一些组分); 所述的固化剂包括下组份: 枣酸丙二醇脂和海藻酸钠, 它们在固
化剂中的重量比例为 0. 33, 也就是枣酸丙二醇脂 0. 2份, 海藻酸钠 0. 6份。 先取固化剂、 赋形剂加入水中, 混合均匀到 85°C〜90°C至完全溶解; 将含 固化剂、 赋形剂的水溶液加入到丙二醇中, 混合均匀, 再升温到 85°C〜90°C。 混合溶液降于冷柜中降温至 -10eC〜- 2(TC, 得固态的电子烟雾化组合物, 也就 是纯净的电子烟雾化膏, 可保持固态膏状, 使用方便。 The excipients are 3.0 parts, the curing agent is 0.8 parts, the propylene glycol is 60 parts, and the deionized water is 20 parts; the excipient consists of: xanthan gum and casein phosphopeptide, which are in the excipient The weight ratio is 0.5, that is, 1 part of xanthan gum, 2 parts of casein phosphopeptide (of course, other components may be included in other embodiments); the curing agent includes the following components: Acid propylene glycol ester and sodium alginate, they are solid 2份。 Sodium alginate 0. 6份。 The weight ratio of 0. 33, that is, propylene glycol methacrylate 0. 2 parts, sodium alginate 0. 6 parts. First take the curing agent, excipients into the water, mix evenly to 85 ° C ~ 90 ° C to completely dissolve; add the aqueous solution containing curing agent, excipients into the propylene glycol, mix evenly, and then heat to 85 ° C ~ 90 °C. The mixed solution is lowered in a freezer to a temperature of -10 e C~- 2 (TC, a solid electronic aerosolized composition, that is, a pure electronic aerosolized paste, which can be kept in a solid paste and is convenient to use.
实施例 2 Example 2
在实施例 1的基础上, 取柠檬酸 0. 15份(15%)、 明胶 0. 2份(20%)、水 0. 5 份(50%)、 丙三醇 0. 15份(15%), 混合均匀, 升温至 80°C, 保持 5小时, 反应 制得果胶酸钙凝胶 1份。 5份(15%), citrate 0. 15 parts (15%), gelatin 0.2 parts (20%), water 0.5 parts (50%), glycerol 0. 15 parts (15%) The mixture was uniformly mixed, and the temperature was raised to 80 ° C for 5 hours to obtain 1 part of a calcium pectate gel.
然后组成药用保健型固体电子雾化组合物, 组成为: 丙二醇 60份, 去离子 水 20份, 赋形剂 3. 0份, 固化剂 0. 8份, 果胶酸钙凝胶 1. 0份, 烟草提取液 3. 5份, 烟草提取液为水剂型的云烟浸膏, 烟用香精 3. 5份, 是玫瑰香精, 药剂 33. 2份。 0份, The calcium pectate gel 1. 0. The composition of the medicinal health-type solid electronic atomization composition, comprising: propylene glycol 60 parts, deionized water 20 parts, excipients 3. 0 parts, curing agent 0. 8 parts, calcium pectate gel 1. 0 5份, The tobacco extract is a liquid-type cloud smoke extract, a tobacco flavor 3. 5 parts, is a rose essence, a medicament 33. 2 parts.
药剂组成为绞股蓝萃取液 30. 0%, 德国洋甘菊萃取液 10. 0%, 酪蛋白磷酸肽 10. 0 %, 蒲公英萃取液 8. 0 %, 黄芪萃取液 8. 0 %, 金银花萃取液 6. 0%,川贝萃 取液 5. 8 %, 菊花萃取液 5. 6 %, 百合萃取液 5. 0 %, 木蝴蝶萃取液 5. 0 %, 酵 素 1. 5 %, 天门冬氨酸 1. 5 %, 辅酶 Q10 1. 33 %, 甘草酸二 钾 1. 0%, 甘草酸单 胺 0. 8%, 牛磺酸 0. 38%, 透明质酸 0. 09%, 它们的总量为 33. 2份。 The medicinal composition of the ginseng extract is 10. 0%, the casein phosphopeptide 1.0. 0%, the dandelion extract 8. 0%, the scutellaria extract 8. 0%, the honeysuckle extract 6. 0%,1,5 %, Aspartic acid 1. 5 %, 蝴蝶 萃取 木 木 木 木 木 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 %%, the total amount of the coenzyme Q10 1. 33%, dipotassium glycyrrhizinate 1. 0%, glycyrrhizic acid monoamine 0. 8%, taurine 0. 38%, hyaluronic acid 0. 09%, their total amount is 33. 2 servings.
并按下列步骤进行制备: And follow the steps below to prepare:
先取固化剂、 陚形剂加入水中, 混合均匀到 85° (:〜 90°C至完全溶解; 将含 固化剂、 赋形剂的水溶液加入到丙二醇中, 混合均匀, 再升温到 85°C〜90°C。 然后降温至 55°C左右加入烟草提取液、 烟用香精、 药剂, 搅拌均匀; 混合溶液
降于冷柜中降温至- 10°C〜- 20° ( , 得类似固态的电子烟雾化组合物, 也就是电 子烟雾化膏, 可保持固态膏状, 使用方便, 雾化稳定。 First, add curing agent and enamel agent to the water, mix evenly to 85 ° (: ~ 90 ° C to completely dissolve; add the aqueous solution containing curing agent and excipient to propylene glycol, mix well, and then heat up to 85 ° C ~ 90 ° C. Then cool down to about 55 ° C to add tobacco extract, tobacco flavor, medicine, stir evenly; mixed solution Lower the temperature in the freezer to -10 ° C ~ - 20 ° (, a solid-like electronic aerosolization composition, that is, electronic aerosolization paste, can maintain a solid paste, easy to use, stable atomization.
实施例 3 Example 3
药用保健型固体电子雾化组合物, 主要组成为: 丙二醇 45份, 药剂 35份, 为绞股蓝萃取液 30. 0, 去离子水 10. 0份, 其余组分与制备方法与实施例 2相 同, 得绞股蓝型的电子烟雾化膏。 可保持固态膏状, 使用方便, 雾化稳定 Medicinal health-type solid electronic atomization composition, the main composition is: propylene glycol 45 parts, 35 parts of medicament, is a Gynostemma extract 30. 0, deionized water 10. 0 parts, the remaining components and preparation method is the same as in the second embodiment , Gynostemma-type electronic aerosolized cream. Can maintain a solid paste, easy to use, stable atomization
实施例 4 Example 4
药用保健型固体电子雾化组合物, 主要组成为: 丙二醇 42份, 药剂 32份, 为绞股蓝萃取液 32. 0份, 去离子水 15. 0份, 其余组分与制备方法与实施例 2 相同, 得绞股蓝型的电子烟雾化膏, 可保持固态膏状, 使用方便, 雾化稳定。 The medicinal health-type solid electronic atomization composition, the main composition is: propylene glycol, 42 parts, 32 parts of the medicament, is a solution of Gynostemma pentaphyllum 32.0 parts, deionized water 15.0 parts, the remaining components and preparation method and Example 2 In the same way, the Gynostemma-type electronic aerosolized paste can maintain a solid paste shape, is convenient to use, and has stable atomization.
本发明可用其它的不违背本发明的精神或主要特征的具体形式来概述。 因 此, 无论从哪一点来看, 本发明的上述实施方案都只能认为是对本发明的说明 而不能限制本发明, 权利要求书指出了本发明的范围, 因此, 在与本发明权利 要求书相当的含义和范围内的任何改变, 都应认为是包括在本发明的范围之内。
The invention may be summarized in other specific forms without departing from the spirit or essential characteristics of the invention. Therefore, the above-described embodiments of the present invention are intended to be illustrative only and not to limit the scope of the invention, and the scope of the present invention is defined by the claims. Any changes in the meaning and scope of the invention are considered to be included within the scope of the invention.
Claims
1. 电子烟雾化组合物, 其包括重量比的如下组份: 赋形剂 2〜3.0份、 固化剂 0.3〜0.8份、 丙二醇或丙三醇 10〜70份、 水 5〜25份; 所述的赋形剂包括 如下组份: 黄原胶和酪蛋白磷酸肽, 它们在赋形剂中的重量比例为 0.25〜 0.67; 所述的固化剂包括下组份: 枣酸丙二醇脂和海藻酸钠, 它们在固化剂 中的重量比例为 0.25〜0.67; 其中丙二醇或丙三醇、 水为溶剂。 An electronic aerosolized composition comprising the following components in a weight ratio: excipient 2 to 3.0 parts, curing agent 0.3 to 0.8 parts, propylene glycol or glycerol 10 to 70 parts, water 5 to 25 parts; Excipients include the following components: xanthan gum and casein phosphopeptides, which are in a weight ratio of 0.25 to 0.67 in the excipient; the curing agent includes the following components: propylene glycol citrate and sodium alginate , their weight ratio in the curing agent is 0.25~0.67; wherein propylene glycol or glycerol, water is a solvent.
2. 根据权利要求 1所述的组合物, 其还包括重量比的如下组份: 所述的果胶酸 钙凝胶 0.2〜1.0份; 所述的果胶酸钙凝胶, 其原料包括果酸 5〜15%、 明胶 20〜40%、 水 40〜60%、 丙三醇 15〜20%; 所述的果酸, 是甘醇酸、 乳酸、 苹 果酸、 酒石酸、 柠檬酸、 杏仁酸之一或其组合。 2. The composition according to claim 1, further comprising the following components in a weight ratio: the calcium pectate gel 0.2 to 1.0 part; the calcium pectate gel, the raw material including the fruit Acid 5~15%, gelatin 20~40%, water 40~60%, glycerol 15~20%; the fruit acid is glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid One or a combination thereof.
3. 根据权利要求 1或 2所述的组合物, 其还包括重量比的如下组份: 药剂 30〜 35份, 或者 /和烟草提取液 3〜3.5份, 或者 /和烟用香精 3〜3.5份。 3. The composition according to claim 1 or 2, further comprising the following components in a weight ratio: 30 to 35 parts of the agent, or / and 3 to 3.5 parts of the tobacco extract, or / and the flavor of the tobacco 3 to 3.5 Share.
4. 根据权利要求 3所述的组合物,所述的药剂的包括如下组份:绞股蓝萃取液、 德国洋甘菊萃取液、 酪蛋白磷酸肽、 蒲公英萃取液、 黄芪萃取液、 金银花萃 取液、 川贝萃取液、 菊花萃取液、 百合萃取液、 木蝴蝶萃取液、 酵素、 天门 冬氨酸、 辅酶 Q10、 甘草酸二钾、 甘草酸单胺、 牛磺酸、 透明质酸之一或组 合, 其重量比为任意比例。 4. The composition according to claim 3, comprising the following components: Gynostemma pentaphyllum extract, German chamomile extract, casein phosphopeptide, dandelion extract, astragalus extract, honeysuckle extract, Chuanbei One or a combination of extract, chrysanthemum extract, lily extract, wood butterfly extract, enzyme, aspartic acid, coenzyme Q10, dipotassium glycyrrhizinate, glycyrrhizic acid monoamine, taurine, hyaluronic acid, and its weight The ratio is any ratio.
5. 根据权利要求 4所述的组合物, 所述的药剂中组份占药剂的重量百分比为: 绞股蓝萃取液 25〜30.0%、 德国洋甘菊萃取液 5〜20.0%、 酪蛋白磷酸肽 5〜 20.0%、 蒲公英萃取液 5〜15.0%、 黄芪萃取液 3〜15.0%、 金银花萃取液 5〜 16.0%、 川贝萃取液 3.8〜: 15.8 %、 菊花萃取液 5〜: 15.6 %、 百合萃取液 4〜 15.0%、 木蝴蝶萃取液 4〜5.0%、 酵素 1〜1.5 %、 天门冬氨酸 0.8〜1.5 %、 辅酶 Q101〜4.33 %、 甘草酸二钾 0.8〜5.0%、 甘草酸单胺 0.5〜3.8%、 牛磺 酸 0.1〜3.38%、 透明质酸 0.01〜4.09%。 The composition according to claim 4, wherein the component of the medicament comprises the weight percentage of the medicament: 25 to 30.0% of Gynostemma pentaphyllum extract, 5 to 20.0% of German chamomile extract, and casein phosphopeptide 5 to 20.0. %, dandelion extract 5~15.0%, astragalus extract 3~15.0%, honeysuckle extract 5~16.0%, Chuanbei extract 3.8~: 15.8 %, chrysanthemum extract 5~: 15.6 %, lily extract 4~ 15.0%, wood butterfly extract 4~5.0%, enzyme 1~1.5%, aspartic acid 0.8~1.5%, coenzyme Q101~4.33%, dipotassium glycyrrhizinate 0.8~5.0%, glycyrrhizic acid monoamine 0.5~3.8% , taurine 0.1~3.38%, hyaluronic acid 0.01~4.09%.
6. 根据权利要求 1〜5任一所述的组合物, 所述的溶剂组份为- 丙二醇 35〜45份、 水 10〜: 15份; The composition according to any one of claims 1 to 5, wherein the solvent component is -propylene glycol 35 to 45 parts, water 10 to 15 parts;
或者丙三醇 35〜45份、 水 10〜15份。 Or 35 to 45 parts of glycerol and 10 to 15 parts of water.
7. 根据权利要求 6所述的组合物, 所述的水为纯净水或者去离子水。 7. The composition according to claim 6, wherein the water is purified water or deionized water.
8. —种权利要求 1所述的电子烟雾化组合物的制备方法, 包括如下步骤: 8. A method of preparing an electronic aerosolized composition according to claim 1, comprising the steps of:
( 1 ) 按权利要求 1所述组份混合均匀并升温至 85°C〜90°C, 得混合溶液; (1) The components according to claim 1 are uniformly mixed and heated to 85 ° C to 90 ° C to obtain a mixed solution;
(2) 上述混合溶液降温至 -10°C〜- 20Ό, 得固态的电子烟雾化组合物。 (2) The above mixed solution is cooled to -10 ° C to - 20 Torr to obtain a solid electronic aerosolized composition.
9. 根据权利要求 8所述的制备方法, 其步骤 (1 ) 具体为: 9. The preparation method according to claim 8, wherein the step (1) is specifically:
先取固化剂、 赋形剂加入水中, 混合均匀到 85°C〜90°C至完全溶解; 将含固化剂、 赋形剂的水溶液加入到丙二醇或者丙三醇中, 混合均匀, 再 升温到 85°C〜90°C。 Firstly, the curing agent and excipients are added to the water, and the mixture is uniformly mixed to 85 ° C to 90 ° C until completely dissolved. The aqueous solution containing the curing agent and the excipient is added to propylene glycol or glycerin, uniformly mixed, and then heated to 85. °C ~ 90 °C.
10.根据权利要求 10所述的制备方法,所述的步骤(2)中的降温的设备为冷柜。 The preparation method according to claim 10, wherein the cooling device in the step (2) is a refrigerator.
11.根据权利要求 10所述的制备方法, 所述的溶剂组份为: The preparation method according to claim 10, wherein the solvent component is:
丙二醇 35〜45份、 水 10〜15份, Propylene glycol 35~45 parts, water 10~15 parts,
或者丙三醇 35〜45份、 水 10〜: 15份。 Or glycerol 35~45 parts, water 10~: 15 parts.
12.根据权利要求 11所述的制备方法, 所述的水为纯净水或者去离子水。 The preparation method according to claim 11, wherein the water is purified water or deionized water.
13.—种权利要求 2所述的电子烟雾化组合物的制备方法, 包括如下步骤: 13. A method of preparing an electronic aerosolized composition according to claim 2, comprising the steps of:
按权 2所述比例的果酸、 明胶、 水、 丙三醇均匀混合, 升温至 70〜90 °C 保持时间, 反应制得果胶酸钙凝胶; The fruit acid, gelatin, water and glycerin in the ratio of 2 are uniformly mixed, and the temperature is raised to 70 to 90 ° C for a holding time to obtain a calcium pectate gel;
( I )按权 2所述含果胶酸钙凝胶的雾化组合物的组份,混合均匀并升温至 85 t:〜 90°C, 得混合溶液; ( II ) 上述混合溶液降温至 - 10°C〜- 20°C, 得固态电子烟雾化组合物。 (I) a component of the atomized composition containing calcium pectate gel according to claim 2, uniformly mixed and heated to 85 t: ~ 90 ° C to obtain a mixed solution; (II) The above mixed solution is cooled to -10 ° C to - 20 ° C to obtain a solid electronic aerosolized composition.
14.根据权利要求 13所述的制备方法, 其步骤 ( I ) 具体为: The preparation method according to claim 13, wherein the step (I) is specifically:
先取固化剂、 果胶酸钙凝胶、 赋形剂加入水中, 混合均匀并升温至 85°C〜 90 °C至完全溶解; First take the curing agent, calcium pectate gel, excipients into the water, mix well and raise the temperature to 85 ° C ~ 90 ° C until completely dissolved;
将含固化剂、 果胶酸钙凝胶、 赋形剂的溶液加入到丙二醇或者丙三醇中, 混合均匀, 再升温到 85eC〜90°C。 A solution containing a curing agent, a calcium pectate gel, and an excipient is added to propylene glycol or glycerin, mixed uniformly, and then heated to 85 e C to 90 °C.
15.根据权利要求 13所述的制备方法, 所述的步骤 (Π ) 中的降温的设备为冷 柜。 The preparation method according to claim 13, wherein the cooling device in the step (Π) is a refrigerator.
16.根据权利要求 13-15任一所述的制备方法, 其中步骤( I )所述的溶剂组份 为: The preparation method according to any one of claims 13 to 15, wherein the solvent component of the step (I) is:
丙二醇 35〜45份、 水 10〜15份; Propylene glycol 35~45 parts, water 10~15 parts;
或者丙三醇 35〜45份、 水 10〜15份。 Or 35 to 45 parts of glycerol and 10 to 15 parts of water.
17.根据权利要求 16所述的制备方法, 其中所述的水为纯净水或者去离子水。 The preparation method according to claim 16, wherein the water is purified water or deionized water.
18. —种权利要求 3所述的电子烟雾化组合物的制备方法, 包括如下步骤:18. The method of preparing an electronic aerosolized composition of claim 3, comprising the steps of:
A:按权 1配方比例取固化剂、赋形剂加入去离子水中, 混合均匀到 85°C〜 90°C至完全溶解, 形成混合溶液; A: according to the right ratio of formula 1 take the curing agent, excipients added to deionized water, mix evenly to 85 ° C ~ 90 ° C until completely dissolved, forming a mixed solution;
B:将混合溶液加入权 1比例的丙二醇或丙三醇中, 混合均匀, 再升温到 85 °C〜90°C ; B: The mixed solution is added to the ratio of propylene glycol or glycerol in a ratio of 1 to be uniformly mixed, and then heated to 85 ° C to 90 ° C;
C:将步骤 B中最终的溶液降温至 40-75°C左右加入烟草提取液 3〜3. 5份,、 或 /和烟用香精 3〜3. 5份, 或 /和药剂 30〜35份, 混合均勾; 5份,或和和药30〜35份。 The C, the final solution in step B is cooled to about 40-75 ° C to add tobacco extract 3~3. 5 parts, or / and tobacco flavor 3~3. 5 parts, or / and 30~35 parts of the medicament , mixed and hooked;
D:将步骤 C中最终的溶液降温至〜 10°C〜- 20°C, 得到固体的电子烟雾化组 合物。 根据权利要求 18所述的制备方法, 其中所述的药剂的包括如下组份: 绞股 蓝萃取液、德国洋甘菊萃取液、酪蛋白磷酸肽、蒲公英萃取液、黄芪萃取液、 金银花萃取液、 川贝萃取液、 菊花萃取液、 百合萃取液、 木蝴蝶萃取液、 酵 素、 天门冬氨酸、 辅酶 Q10、 甘草酸二钾、 甘草酸单胺、 牛磺酸、 透明质酸 之一或组合, 其重量比为任意比例。 D: The final solution in step C was cooled to ~10 ° C to -20 ° C to obtain a solid electronic aerosolized composition. The preparation method according to claim 18, wherein the pharmaceutical agent comprises the following components: Gynostemma pentaphyllum extract, German chamomile extract, casein phosphopeptide, dandelion extract, astragalus extract, honeysuckle extract, Chuanbei extract Liquid, chrysanthemum extract, lily extract, wood butterfly extract, enzyme, aspartic acid, coenzyme Q10, dipotassium glycyrrhizinate, glycyrrhizic acid monoamine, taurine, hyaluronic acid, or a combination thereof, the weight ratio thereof For any ratio.
根据权利要求 19所述的制备方法, 其中所述的药剂的组份占药剂的重量百 分比为: 绞股蓝萃取液 25〜30. 0%、 德国洋甘菊萃取液 5〜20. 0%、 酪蛋白磷 酸肽 5〜20. 0%、 蒲公英萃取液 5〜15. 0%、 黄芪萃取液 3〜15. 0%、 金银花萃 取液 5〜 16. 0%、 川贝萃取液 3. 8〜15. 8 %、 菊花萃取液 5〜15. 6 %、 百合萃 取液 4〜: 15. 0%、 木蝴蝶萃取液 4〜5. 0%、 酵素 1〜: 1. 5 %、 天门冬氨酸 0. 8〜 1. 5 %、辅酶 Q10 1〜4. 33 %、甘草酸二钾 0. 8〜5. 0%、甘草酸单胺 0. 5〜3. 8%、 牛磺酸 0. 1〜3. 38%、 透明质酸 0. 01〜4. 09%。 The method of the present invention, wherein the composition of the pharmaceutical agent comprises a weight percent of the drug: Gynostemma pentaphyllum extract 25~30. 0%, German chamomile extract 5~20. 0%, casein phosphopeptide 0%, 0%, succulent extract 3~15. 0%, honeysuckle extract 5~ 16. 0%, Chuanbei extract 3. 8~15. 8 %, 8〜1,1,1%,1%,1%,1%,1% 5〜3. 38%, coenzyme Q10 1~4. 38%, dipotassium glycyrrhizinate 0. 8~5. 0%, glycyrrhizic acid monoamine 0. 5~3. 8%, taurine 0. 1~3. 38% 01〜4. 09%。 Hyaluronic acid 0. 01~4. 09%.
根据权利要求 19所述的制备方法, 其中步骤 C中所述的温度为 55°C。 The production method according to claim 19, wherein the temperature in the step C is 55 °C.
根据权利要求 18所述的制备方法, 所述的步骤 D中的降温的设备为冷柜。 根据权利要求 18-22任一所述的制备方法, 其中所述的溶剂组份为: 丙二醇 35〜45份、 水 10〜15份; The preparation method according to claim 18, wherein the cooling device in the step D is a refrigerator. The preparation method according to any one of claims 18 to 22, wherein the solvent component is: propylene glycol 35 to 45 parts, water 10 to 15 parts;
或者丙三醇 35〜45份、 水 10〜15份。 Or 35 to 45 parts of glycerol and 10 to 15 parts of water.
根据权利要求 23所叙述的制备方法, 其中所述的水为纯净水或者去离子水。 —种权利要求 3所述的电子烟雾化组合物的制备方法, 包括如下步骤: The production method according to claim 23, wherein said water is purified water or deionized water. A method of preparing an electronic aerosolized composition according to claim 3, comprising the steps of:
按权 2所述比例的果酸、 明胶、 水、 丙三醇合均匀混合, 升温至 70〜90 °C, 保持时间, 反应制得果胶酸钙凝胶; The fruit acid, gelatin, water and glycerin in the ratio of 2 are uniformly mixed, and the temperature is raised to 70 to 90 ° C for a hold time to obtain a calcium pectate gel;
A: 按权 2比例取固化剂、 果胶酸钙凝胶、 赋形剂加入去离子水中, 升温搅 拌到 85° ( 〜 90°C至完全溶解, 形成混合溶液; A: The curing agent, calcium pectate gel and excipients are added to deionized water at a ratio of 2, and the temperature is stirred. Mix at 85 ° (~ 90 ° C until completely dissolved to form a mixed solution;
B:将混合溶液加入到权 1 比例的丙二醇或丙三醇中, 混合均匀, 再升温到 85°C〜90°C ; B: adding the mixed solution to the ratio of propylene glycol or glycerol in a ratio of 1 , mixing uniformly, and then heating to 85 ° C ~ 90 ° C;
C :将步骤 B中最终的溶液降温至 40-75°C左右加入烟草提取液 3〜3. 5份, 或 /和烟用香精 3〜3. 5份, 或 /和药剂 30〜35份, 混合均匀; 5份, or / and 30-35 parts of the medicament, the tobacco solution is added to the tobacco extract 3~3. 5 parts, or / and the tobacco flavor 3~3. 5 parts, or / and the medicament 30~35 parts, well mixed;
D:将步骤 C中最终的溶液降温至〜 1CTC〜- 20°C, 得到固体的电子烟雾化组 合物。 D: The final solution in the step C was cooled to ~1 CTC to - 20 ° C to obtain a solid electron atomization composition.
根据权利要求 25所述的制备方法, 其中所述的药剂的包括如下组份: 绞股 蓝萃取液、德国洋甘菊萃取液、酪蛋白磷酸肽、蒲公英萃取液、黄芪萃取液、 金银花萃取液、 川贝萃取液、 菊花萃取液、 百合萃取液、 木蝴蝶萃取液、 酵 素、 天门冬氨酸、 辅酶 Q10、 甘草酸二钾、 甘草酸单胺、 牛磺酸、 透明质酸 之一或组合, 其重量比为任意比例。 The preparation method according to claim 25, wherein the pharmaceutical agent comprises the following components: Gynostemma pentaphyllum extract, German chamomile extract, casein phosphopeptide, dandelion extract, astragalus extract, honeysuckle extract, Chuanbei extract Liquid, chrysanthemum extract, lily extract, wood butterfly extract, enzyme, aspartic acid, coenzyme Q10, dipotassium glycyrrhizinate, glycyrrhizic acid monoamine, taurine, hyaluronic acid, or a combination thereof, the weight ratio thereof For any ratio.
根据权利要求 26所述的制备方法, 其中所述的药剂的组份占药剂的重量百 分比为: 绞股蓝萃取液 25〜30. 0%、 德国洋甘菊萃取液 5〜20. 0%、 酪蛋白磷 酸肽 5〜20. 0%、 蒲公英萃取液 5〜15. 0%、 黄芪萃取液 3〜15. 0%、 金银花萃 取液 5〜 16. 0%、 川贝萃取液 3. 8〜15. 8 %、 菊花萃取液 5〜15. 6 %、 百合萃 取液 4〜15. 0%、 木蝴蝶萃取液 4〜5. 0%、 酵素 1〜1. 5 %、 天门冬氨酸 0. 8〜 1. 5 %、辅酶 Q10 1〜4. 33 %、甘草酸二钾 0. 8〜5. 0%、甘草酸单胺 0. 5〜3. 8%、 牛磺酸 0. 1〜3. 38%、 透明质酸 0. 01〜4. 09%。 The method of claim 26, wherein the component of the pharmaceutical agent comprises a weight percent of the drug: Gynostemma pentaphyllum extract 25~30. 0%, German chamomile extract 5~20. 0%, casein phosphopeptide 0%, 0%, succulent extract 3~15. 0%, honeysuckle extract 5~ 16. 0%, Chuanbei extract 3. 8~15. 8 %, The sucrose extract is 5~15. 6%, the extract of the lily is 4~15. 0%, the extract of the wood butterfly is 4~5. 0%, the enzyme is 1~1. 5 %, aspartic acid 0. 8~ 1. 5 8%, 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 01〜4. 09%.
根据权利要求 26所述的制备方法, 其中所述的步骤 C中的温度为 55°C。 根据权利要求 25所述的制备方法, 其中所述的步骤 D中的降温的设备为冷 柜。 根据权利要求 25〜29任一所述的制备方法, 所述的溶剂组份为: The production method according to claim 26, wherein the temperature in the step C is 55 °C. The preparation method according to claim 25, wherein the temperature-lowering device in the step D is a refrigerator. The preparation method according to any one of claims 25 to 29, wherein the solvent component is:
丙二醇 35〜45份、 水 10〜15份; Propylene glycol 35~45 parts, water 10~15 parts;
或者丙三醇 35〜45份、 水 10〜15份。 Or 35 to 45 parts of glycerol and 10 to 15 parts of water.
根据权利要求 30所述的制备方法, 其中所述的水为纯净水或者去离子水。 —种果胶酸钙凝胶, 其原料包括果酸 5〜15%、 明胶 20〜40%、 水 40〜70%、 丙三醇 15〜20°/0。 The production method according to claim 30, wherein the water is purified water or deionized water. - a calcium pectate gel, the raw materials including 5 to 15% of fruit acid, 20 to 40% of gelatin, 40 to 70% of water, and 15 to 20 ° / 0 of glycerol.
根据权利要求 32所述的果胶酸钙凝胶, 其中所述的果酸, 是甘醇酸、 乳酸、 苹果酸、 酒石酸、 柠檬酸、 杏仁酸之一或其组合。 The calcium pectate gel according to claim 32, wherein the fruit acid is one of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid or a combination thereof.
—种如权利要求 32所述的果胶酸钙凝胶的制备方法: 取果酸 5〜15%、 明胶 20〜40%、 水 40〜60%、 丙三醇 15〜20%, 混合均匀, 升温至 70〜90°C, 保持 时间, 反应制得果胶酸钙凝胶。 A method for preparing a calcium pectate gel according to claim 32, which comprises 5 to 15% of fruit acid, 20 to 40% of gelatin, 40 to 60% of water, 15 to 20% of glycerin, and is uniformly mixed. The temperature was raised to 70 to 90 ° C for a hold time to obtain a calcium pectate gel.
根据权利要求其 34所述制备方法, 其中所述的果酸, 是甘醇酸、 乳酸、 苹 果酸、 酒石酸、 柠檬酸、 杏仁酸之一或其组合。 The preparation method according to Claim 34, wherein the fruit acid is one of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid or a combination thereof.
根据权利要求 35所述制备方法, 其中所述的保持时间为 1-20小时。 The production method according to claim 35, wherein said holding time is from 1 to 20 hours.
—种权利要求 32所述的果胶酸钙凝胶在电子烟雾化组合物中作为雾化稳定 剂的应用。 Use of the calcium pectate gel of claim 32 as an atomization stabilizer in an electronic aerosolized composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010249133A CN101933653B (en) | 2010-08-09 | 2010-08-09 | Officinal health-care solid electronic aerosolization liquid and preparation method thereof |
CN201010249133.4 | 2010-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012019533A1 true WO2012019533A1 (en) | 2012-02-16 |
Family
ID=43387400
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/076374 WO2012019372A1 (en) | 2010-08-09 | 2010-08-26 | Medicinal healthcare solid electronic cigarette atomizing solution and preparation thereof |
PCT/CN2011/078133 WO2012019533A1 (en) | 2010-08-09 | 2011-08-08 | Electronic cigarette's atomization composition with calcium pectate gel and preparation process and use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/076374 WO2012019372A1 (en) | 2010-08-09 | 2010-08-26 | Medicinal healthcare solid electronic cigarette atomizing solution and preparation thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101933653B (en) |
WO (2) | WO2012019372A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10034988B2 (en) | 2012-11-28 | 2018-07-31 | Fontem Holdings I B.V. | Methods and devices for compound delivery |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
US10045567B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
US10045568B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
US10058130B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
US10104915B2 (en) | 2013-12-23 | 2018-10-23 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
US10111470B2 (en) | 2013-12-23 | 2018-10-30 | Juul Labs, Inc. | Vaporizer apparatus |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
US10194693B2 (en) | 2013-09-20 | 2019-02-05 | Fontem Holdings 1 B.V. | Aerosol generating device |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
US10512282B2 (en) | 2014-12-05 | 2019-12-24 | Juul Labs, Inc. | Calibrated dose control |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
US10772352B2 (en) | 2014-10-29 | 2020-09-15 | Altria Client Services Llc | Ethanol-free gel formulation cartridge for e-vaping device |
US10849358B2 (en) | 2014-10-29 | 2020-12-01 | Altria Client Services Llc | E-vaping cartridge |
US10865001B2 (en) | 2016-02-11 | 2020-12-15 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US12114688B2 (en) | 2017-10-24 | 2024-10-15 | Rai Strategic Holdings, Inc. | Method for formulating aerosol precursor for aerosol delivery device |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101933653B (en) * | 2010-08-09 | 2012-10-10 | 深圳市如烟生物科技有限公司 | Officinal health-care solid electronic aerosolization liquid and preparation method thereof |
CN102349699B (en) * | 2011-07-04 | 2013-07-03 | 郑俊祥 | Preparation method for electronic cigarette liquid |
CN102960852B (en) * | 2012-11-14 | 2015-04-22 | 湖北中烟工业有限责任公司 | Light-fragrance electronic cigarette atomized smoke solution and preparation method thereof |
CN103054172A (en) * | 2013-01-25 | 2013-04-24 | 红云红河烟草(集团)有限责任公司 | Electronic cigarette liquid prepared from strong-flavor tobacco leaves |
CN103054173A (en) * | 2013-01-25 | 2013-04-24 | 红云红河烟草(集团)有限责任公司 | Electronic cigarette liquid prepared from inferior tobacco leaves |
CN103054171A (en) * | 2013-01-25 | 2013-04-24 | 红云红河烟草(集团)有限责任公司 | Electronic cigarette liquid prepared from middle-flavor tobacco leaves |
CN103070472A (en) * | 2013-01-25 | 2013-05-01 | 红云红河烟草(集团)有限责任公司 | Electronic cigarette liquid capable of effectively improving sensory quality of electronic cigarette |
CN103070473A (en) * | 2013-01-25 | 2013-05-01 | 红云红河烟草(集团)有限责任公司 | Electronic cigarette liquid prepared from fen-flavor tobacco leaves |
CN103535851B (en) * | 2013-10-22 | 2015-11-18 | 深圳市凯神科技股份有限公司 | solid tobacco tar and processing method thereof |
CN103768367B (en) * | 2014-01-21 | 2016-08-31 | 江苏中烟工业有限责任公司 | A kind of expelling phlegm for arresting cough type tobacco oral spray agent and preparation method thereof |
CN103767063B (en) * | 2014-01-21 | 2016-03-16 | 江苏中烟工业有限责任公司 | A kind of anti-blooming antiemetic type tobacco oral spray agent and preparation method thereof |
CN103768435B (en) * | 2014-01-21 | 2016-06-15 | 江苏中烟工业有限责任公司 | A kind of fresh breath type tobacco oral spray agent and preparation method thereof |
CN103750573B (en) * | 2014-01-23 | 2017-03-08 | 深圳市凯神科技股份有限公司 | Electronic cigarette tobacco tar and preparation method thereof |
CN105876863A (en) * | 2014-05-04 | 2016-08-24 | 深圳市施美乐科技股份有限公司 | Composite functional type electronic cigarette atomized liquid and preparation method thereof |
CN103932383B (en) * | 2014-05-12 | 2016-05-25 | 华健 | The electronic oral cavity atomized liquid that a kind of polynary ethylene glycol series low-carbon alcohols is base fluid |
CN103960784A (en) * | 2014-05-15 | 2014-08-06 | 湖北中烟工业有限责任公司 | Gel type disposable electronic cigarette cartridge with electric heating wire arranged internally and with liquid fixed and preparation method thereof |
CN103960783A (en) * | 2014-05-15 | 2014-08-06 | 湖北中烟工业有限责任公司 | Gel type solid-liquid electronic cigarette cartridge and manufacturing method thereof |
CN104256888B (en) * | 2014-08-07 | 2016-06-22 | 江苏中烟工业有限责任公司 | A kind of heat-sensitive electronic tobacco juice and preparation thereof |
CN105326087A (en) * | 2014-08-12 | 2016-02-17 | 佛山市万绿素电子科技有限公司 | Electronic cigarette tobacco tar with functions of alleviating hangover and protecting liver |
CN104382224A (en) * | 2014-10-22 | 2015-03-04 | 浙江中烟工业有限责任公司 | Solid state cartridge for electronic cigarettes and preparation method thereof |
CN104489913A (en) * | 2014-12-17 | 2015-04-08 | 贵州中烟工业有限责任公司 | E-cigarette nicotine liquid with functions of heat clearing and fire removing |
CN104489911A (en) * | 2014-12-17 | 2015-04-08 | 贵州中烟工业有限责任公司 | Tobacco juice of electronic cigarette |
CN104489904A (en) * | 2014-12-17 | 2015-04-08 | 贵州中烟工业有限责任公司 | E-cigarette nicotine liquid with functions of relieving cough and reducing sputum |
CN104664589B (en) * | 2014-12-31 | 2016-09-21 | 广东金成生物科技工程有限公司 | A kind of atomized liquid containing Korean Ginseng composition and preparation method thereof |
CN104664586B (en) * | 2014-12-31 | 2016-11-30 | 广东金成生物科技工程有限公司 | A kind of atomized liquid containing astragalus root components and preparation method thereof |
CN104585868A (en) * | 2015-01-20 | 2015-05-06 | 川渝中烟工业有限责任公司 | Human body essential amino acid-rich electronic cigarette juice |
CN104585866B (en) * | 2015-01-20 | 2016-03-30 | 川渝中烟工业有限责任公司 | Ultrasonic atomizatio electronic cigarette liquid being rich in bioactive polysaccharide and preparation method thereof |
CN104585872A (en) * | 2015-01-20 | 2015-05-06 | 川渝中烟工业有限责任公司 | Electronic cigarette liquid containing water soluble propolis and preparation method thereof |
CN104621705B (en) * | 2015-01-20 | 2016-02-03 | 川渝中烟工业有限责任公司 | A kind of tobacco juice for electronic smoke containing mushroom ma extract |
CN104585870B (en) * | 2015-01-20 | 2016-08-17 | 川渝中烟工业有限责任公司 | A kind of tobacco juice for electronic smoke with relieving cough and moistening lung function |
CN104770868A (en) * | 2015-04-14 | 2015-07-15 | 刘东原 | Electronic cigarette liquid containing nutritional components or medicinal components |
CN104872814A (en) * | 2015-05-05 | 2015-09-02 | 昌宁德康生物科技有限公司 | Production method for extracting tobacco leaf clean oil |
CN104983065B (en) * | 2015-08-13 | 2017-04-12 | 深圳市施美乐科技股份有限公司 | Electron aerosolization liquid with human body function nursing effect |
CN105686060B (en) * | 2016-03-10 | 2017-06-06 | 四川中烟工业有限责任公司 | Mild cigar type electronic cigarette and preparation method thereof |
GB2560299B (en) | 2017-02-01 | 2021-07-07 | Nicoventures Trading Ltd | Heating element and method of analysing |
GB201701633D0 (en) | 2017-02-01 | 2017-03-15 | Nicoventures Holdings Ltd | Heating element selection method |
GB201718031D0 (en) * | 2017-11-01 | 2017-12-13 | British American Tobacco Investments Ltd | Aerosolisable gel |
GB201718032D0 (en) | 2017-11-01 | 2017-12-13 | British American Tobacco Investments Ltd | Aerosolisable gel |
UA127833C2 (en) | 2018-04-06 | 2024-01-17 | Філіп Морріс Продактс С.А. | Nicotine gel |
CN112237299A (en) * | 2019-07-16 | 2021-01-19 | 王振宁 | Smokeless electronic cigarette tobacco tar and preparation method thereof |
CN110754685B (en) * | 2019-11-12 | 2022-03-22 | 广东中烟工业有限责任公司 | Cigarette with low harmful components in smoke and preparation method thereof |
CN111202259A (en) * | 2020-02-25 | 2020-05-29 | 深圳市德森生物科技有限公司 | Smoke-free electronic cigarette liquid and preparation method thereof |
CN111449272A (en) * | 2020-04-20 | 2020-07-28 | 桂方晋 | Novel atomized solid matrix and preparation process thereof |
CN112220102B (en) * | 2020-09-25 | 2022-12-09 | 山东华熙海御生物医药有限公司 | Electronic cigarette liquid containing hyaluronic acid and ectoine and preparation method thereof |
CN113273716B (en) * | 2021-05-19 | 2022-05-03 | 深圳市真味生物科技有限公司 | Atomized liquid gel and preparation process thereof |
CN117256920A (en) * | 2023-09-27 | 2023-12-22 | 东莞市吉纯生物技术有限公司 | Solid atomized matter and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1931040A (en) * | 2006-09-29 | 2007-03-21 | 冯相斌 | Solution for electronic intelligent atomized cigarette and its prepn process |
CN101461565A (en) * | 2009-01-08 | 2009-06-24 | 华健 | Medicinal health type tobacco juice for electronic smoke |
CN101473999A (en) * | 2009-01-21 | 2009-07-08 | 华健 | Health-care type electronic smoke liquid for preventing and treating decayed tooth |
CN1994159B (en) * | 2006-12-15 | 2010-05-26 | 姜志荣 | Kidney-strengthening mind-refreshing tobacco liquid for electronic atomized cigarette |
CN101933653A (en) * | 2010-08-09 | 2011-01-05 | 深圳市如烟生物科技有限公司 | Officinal health-care solid electronic aerosolization liquid and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004289248B2 (en) * | 2003-11-07 | 2012-05-03 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
CN101731750B (en) * | 2008-03-26 | 2012-08-22 | 修运强 | Atomized liquid of electronic simulation cigarette |
CN101461566B (en) * | 2009-01-08 | 2012-01-18 | 华健 | Atomized liquid of electronic smoke |
-
2010
- 2010-08-09 CN CN201010249133A patent/CN101933653B/en not_active Expired - Fee Related
- 2010-08-26 WO PCT/CN2010/076374 patent/WO2012019372A1/en active Application Filing
-
2011
- 2011-08-08 WO PCT/CN2011/078133 patent/WO2012019533A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1931040A (en) * | 2006-09-29 | 2007-03-21 | 冯相斌 | Solution for electronic intelligent atomized cigarette and its prepn process |
CN1994159B (en) * | 2006-12-15 | 2010-05-26 | 姜志荣 | Kidney-strengthening mind-refreshing tobacco liquid for electronic atomized cigarette |
CN101461565A (en) * | 2009-01-08 | 2009-06-24 | 华健 | Medicinal health type tobacco juice for electronic smoke |
CN101473999A (en) * | 2009-01-21 | 2009-07-08 | 华健 | Health-care type electronic smoke liquid for preventing and treating decayed tooth |
CN101933653A (en) * | 2010-08-09 | 2011-01-05 | 深圳市如烟生物科技有限公司 | Officinal health-care solid electronic aerosolization liquid and preparation method thereof |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
US10034988B2 (en) | 2012-11-28 | 2018-07-31 | Fontem Holdings I B.V. | Methods and devices for compound delivery |
US10638792B2 (en) | 2013-03-15 | 2020-05-05 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US10194693B2 (en) | 2013-09-20 | 2019-02-05 | Fontem Holdings 1 B.V. | Aerosol generating device |
US10104915B2 (en) | 2013-12-23 | 2018-10-23 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10070669B2 (en) | 2013-12-23 | 2018-09-11 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
US10111470B2 (en) | 2013-12-23 | 2018-10-30 | Juul Labs, Inc. | Vaporizer apparatus |
US10117465B2 (en) | 2013-12-23 | 2018-11-06 | Juul Labs, Inc. | Vaporization device systems and methods |
US10117466B2 (en) | 2013-12-23 | 2018-11-06 | Juul Labs, Inc. | Vaporization device systems and methods |
US11752283B2 (en) | 2013-12-23 | 2023-09-12 | Juul Labs, Inc. | Vaporization device systems and methods |
US10667560B2 (en) | 2013-12-23 | 2020-06-02 | Juul Labs, Inc. | Vaporizer apparatus |
US10058124B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
US10201190B2 (en) | 2013-12-23 | 2019-02-12 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10912331B2 (en) | 2013-12-23 | 2021-02-09 | Juul Labs, Inc. | Vaporization device systems and methods |
US10045568B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
US10264823B2 (en) | 2013-12-23 | 2019-04-23 | Juul Labs, Inc. | Vaporization device systems and methods |
US10058130B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10045567B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
US10701975B2 (en) | 2013-12-23 | 2020-07-07 | Juul Labs, Inc. | Vaporization device systems and methods |
US10772352B2 (en) | 2014-10-29 | 2020-09-15 | Altria Client Services Llc | Ethanol-free gel formulation cartridge for e-vaping device |
US11825566B2 (en) | 2014-10-29 | 2023-11-21 | Altria Client Services Llc | E-vaping cartridge |
US10849358B2 (en) | 2014-10-29 | 2020-12-01 | Altria Client Services Llc | E-vaping cartridge |
US10512282B2 (en) | 2014-12-05 | 2019-12-24 | Juul Labs, Inc. | Calibrated dose control |
US10865001B2 (en) | 2016-02-11 | 2020-12-15 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
USD929036S1 (en) | 2016-06-16 | 2021-08-24 | Pax Labs, Inc. | Vaporizer cartridge and device assembly |
USD913583S1 (en) | 2016-06-16 | 2021-03-16 | Pax Labs, Inc. | Vaporizer device |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
US12114688B2 (en) | 2017-10-24 | 2024-10-15 | Rai Strategic Holdings, Inc. | Method for formulating aerosol precursor for aerosol delivery device |
Also Published As
Publication number | Publication date |
---|---|
CN101933653A (en) | 2011-01-05 |
WO2012019372A1 (en) | 2012-02-16 |
CN101933653B (en) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012019533A1 (en) | Electronic cigarette's atomization composition with calcium pectate gel and preparation process and use thereof | |
EP3232825B1 (en) | An oral smokeless moist snuff product | |
WO2021017137A1 (en) | Chewing gum, e-liquid and use thereof | |
CN103191080B (en) | Acetylcysteine effervescent tablet | |
WO2021036121A1 (en) | E-liquid | |
CN105412049B (en) | Medicinal composition for dry powder inhalant and preparation method thereof | |
CN114868955B (en) | Nicotine salt preparation method, nicotine salt and aerosol product | |
CN101829036A (en) | Oral spray | |
CN103705476B (en) | Ilaprazole freeze-dried powder injection and preparation method thereof | |
CA3181666A1 (en) | New compositions for oral or nasal use | |
JP2021506897A (en) | Solution formulation for aerosol inhalation of hoodstain and its manufacturing method | |
CN106659751A (en) | Orodispersible film | |
KR20140140021A (en) | Nicotine formulation | |
CN105106142B (en) | It is a kind of containing according to lyophilized oral formulations of piperazine azoles and preparation method thereof | |
JP6461902B2 (en) | Miniaturized pharmaceutical composition | |
US20200261362A1 (en) | Solution Preparation for Aerosol Inhalation of Carbocisteine, and Preparation Method Therefor | |
CN104689035A (en) | Aerosol precursor containing pharmacodynamic ingredients of Chuanbei Pipa syrup and method for dispersing aerosol precursor into nano-scale frog drops | |
CN100348215C (en) | Kaihoujian drip pill for treating throat disease and its preparation method | |
CN105997539A (en) | Anti-inflammatory and analgesic traditional Chinese medicinal toothpaste | |
CN106620673A (en) | Hydrogel for treating infant dental ulcer and preparation method of hydrogel | |
NL2029429B1 (en) | Preparation method and application of atomizing mixture for electronic atomizer | |
WO2022077219A1 (en) | Composition, preparation method, and tea cartridge | |
CN102525979A (en) | Infant ibuprofen composition | |
CN102614212A (en) | Freeze-dried orally disintegrating tablets of pediatric ribavirin composition, and preparation method thereof | |
CN102485216A (en) | Taste-modifying medicine tablets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11816091 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A, DATED 14-06-2013) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11816091 Country of ref document: EP Kind code of ref document: A1 |